Exscientia presented novel patient stratification and biomarker data for GTAEXS-617 at the 34th EORTC-NCI-AACR Annual Symposium

Exscientia plc (Nasdaq: EXAI) today released important new data to include more patients
at risk of responding to its precisely designed CDK7 inhibitor, GTAEXS-617 ('617).
This study confirmed a CDK7-specific pharmacodynamic (PD) biomarker, revealed potential novel PD markers, and identified a preliminary novel gene expression profile
for screening patients.
The planned Phase 1/2 study will partially assess
this characteristic.
Exscientia is presenting data
at the 34th EORTC-NCI-AACR (ENA 2022) Symposium on Molecular Targets and Cancer Therapeutics.
The conference was held
in Barcelona, Spain, on October 26-28, 2022.

In this study, researchers leveraged Exscientia's translational oncology platform, combined with AI-based primary cancer tissue analysis and transcriptomics, to understand how cells in different patient populations respond to '617 treatment
.
The results showed that some patient samples showed differentiated sensitivity
.
Exscientia is thus able to correlate responses with the genomic and phenotypic characteristics of individual patients
.
These correlations can then be used to determine which patients are most likely to respond to '617 therapy for inclusion in upcoming clinical trials
.

In addition, the data show that '617 induces less immune cell death than selected CDK4/6 and other CDK7 inhibitors under investigation, potentially demonstrating a differentiated clinical safety profile
.
Current clinical trials of new drugs are targeting '617 as a potential treatment for
transcriptional addictive cancers.

Gregory Vladimer, vice president of translational research at Exscientia, said: "We are excited to present the new data
.
These data support our translational platform to rapidly assess the activity of novel targeted therapies that have the potential to improve clinical outcomes
for patients.
Based on a functional precision medicine platform, combined with single-cell transcriptomics and AI modeling of primary disease tissue, I believe we are uniquely positioned to conduct more research on patient populations that are more likely to respond to or not respond to a therapy, thereby actually improving cancer outcomes
for patients.
" ”

Poster Presentation Details: Determination of Activity and Patient Selection
of the Novel CDK7 Inhibitor GTAEXS-617 by AI-Supported Primary Cancer Tissue Analysis Poster Session: Preclinical Model
Summary Number: #124
Date/Time: Wednesday, October 26 from 12:00 p.
m.
to 8:
00 p.
m.
CET

GTAEXS-617 is a novel CDK7 inhibitor designed by Exscientia in collaboration with GT Apeiron, with high potency, selectivity, bioavailability and safety
.
CDK7 inhibition combines cell cycle disruption and transcriptional inhibition, making it an attractive target for overcoming the resistance pathways common in CDK4/6 inhibition
.

Exscientia is expected to submit a clinical trial application (CTA) by the end of 2022 and initiate Phase 1/2 clinical trials
in multiple solid tumor indications, including ovarian cancer, in the first half of 2023.